Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

PURPOSE: CALGB 40601 assessed whether dual versus single human epidermal growth factor receptor 2 (HER2) –targeting drugs added to neoadjuvant chemotherapy increased pathologic complete response (pCR). Here, we report relapse-free survival (RFS), overall survival (OS), and gene expression signatures...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Fernandez-Martinez, Aranzazu, Krop, Ian E., Hillman, David W., Polley, Mei-Yin, Parker, Joel S., Huebner, Lucas, Hoadley, Katherine A., Shepherd, Jonathan, Tolaney, Sara, Henry, N. Lynn, Dang, Chau, Harris, Lyndsay, Berry, Donald, Hahn, Olwen, Hudis, Clifford, Winer, Eric, Partridge, Ann, Perou, Charles M., Carey, Lisa A.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2020
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7723687/
https://ncbi.nlm.nih.gov/pubmed/33095682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01276
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars